Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN84,3584,380,39
Msft1,58
Nokia4,3894,48-0,27
IBM1,50
Mercedes-Benz Group AG50,1950,21-1,01
PFE0,24
04.07.2025 18:00:42
Indexy online
AD Index online
select
AD Index online
 

  • 03.07.2025 23:00:00
Dyne Therapeutcs Rg (NASDAQ Cons)
Závěr k 3.7.2025 Změna (%) Změna (USD) Objem obchodů (ks)
8,76 -2,01 -0,18 1 988 964
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 05.07.2025
Popis společnosti
Obecné informace
Název společnostiDyne Therapeutics Inc
TickerDYN
Kmenové akcie:Ordinary Shares
RICDYN.O
ISIN-
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.03.2025
Počet zaměstnanců k 31.03.2025 192
Akcie v oběhu k 30.06.2025 137 876 207
MěnaUSD
Kontaktní informace
Ulice1560 Trapelo Road
MěstoWALTHAM
PSČ02451
ZeměUnited States
Kontatní osobaAmy Reilly
Funkce kontaktní osobySenior Vice President - Corporate Communications and Investor Relations
Telefon17 817 868 230
Fax17817868866

Business Summary: Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Dyne Therapeutics Inc revenues was not reported. Net loss increased 76% to $115.4M. Higher net loss reflects PHARMACEUTICAL PREPARATIONS segment loss increase of 77% to $122.4M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.81 to -$1.05.
Odvětvová klasifikace
TRBC2012Bio Therapeutic Drugs
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICS2007Research and Development in Biotechnology
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Biological Product (except Diagnostic) Manufacturing
SICCommercial Physical Research



  • Poslední aktualizace: 05.07.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorJohn Cox6225.03.2024
Chief Financial Officer, TreasurerErick Lucera5731.03.202531.03.2025
Chief Scientific OfficerRanjan Batra-28.04.202528.04.2025
Chief Innovation OfficerOxana Beskrovnaya6428.04.2025
Chief Commercial OfficerJohanna Friedl- Naderer5703.09.202403.09.2024
Chief Medical OfficerDoug Kerr5803.09.202403.09.2024
Chief Business OfficerVikram Ranade-15.04.202515.04.2025